Dr. John Cush RheumNow
1 year 11 months ago
SPRINGBOARD: Extended-release Intra-articular Corticosteroid Injection in Knee OA
A phase 2 trial of EP-104IAR (long-acting, fluticasone propionate) has shown 14 weeks of clinically meaningful pain relief in knee osteoarthritis (OA). This intra-articular formulation is… https://t.co/IjlEDMmzzH https://t.co/Ly40yQgZ8e
Dr. John Cush RheumNow
1 year 11 months ago
Calcium pyrophosphate deposition disease -- a full access, full read review in Lancet Rheumatology. Just published ahttps://buff.ly/3C319CH https://t.co/PxywxvzVCh
Dr. John Cush RheumNow
1 year 11 months ago
Nailfold videocapillaroscopy (NVC) study of 65 Behcets pts found vascular abnl in 40-47% ( enlarged/tortuous capillaries, microhaemorrhages. Having ≥2 NVC abnormalities increase risk of Vascular events (VTE, superficial thrombophlebitis), but not ANA https://t.co/2Om0IIFVnG https://t.co/W7mbdPh9ee
Dr. John Cush RheumNow
1 year 11 months ago
Pain Relief in RA: JAK Better than TNF Inhibitors?
Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.
https://t.co/olXQMGm2h8 https://t.co/Em7ydT33Ui
Dr. John Cush RheumNow
1 year 11 months ago
Ganglion cysts are thin walled cavities contain a viscous, mucinous fluid, arising in proximity to joint capsules/tendon sheaths but do not communicate with the joint. Most common w/ repetitive strain or overuse, trauma, or inflam. arthritis. Steroid injx dont… https://t.co/nUlQvemYa5 https://t.co/gSNzBuPeW4
Dr. John Cush RheumNow
1 year 11 months ago
RBC mitochondrial DNA triggers type I interferon (IFN) production in macrophages leading to production of interleukin-1β and inflammasome activation - Making IFN & IL-1B monocytes another potential therapeutic target in #SLE https://t.co/DeZH1RT3GC https://t.co/jojAhNoNzA https://t.co/lPuOQxvmVb
Dr. John Cush RheumNow
1 year 11 months ago
Full read review on the detection & management of #ILD in Autoimmune Dz (AID).
- AID at risk for ILD should be screened with hi-res CT Scan
- ILD should be monitored closely w/ PFTs
- Multidisciplinary Rx includes immunosuppressives & antifibrotics https://t.co/X6Feor2wF5 https://t.co/Z2WBWL3q1W
Dr. John Cush RheumNow
1 year 11 months ago
Early bird pricing ends 10/31. Secure your seat for RheumNow Live today!
https://t.co/TBNLxfBbEF https://t.co/6OLHEXCvUw
Dr. John Cush RheumNow
1 year 11 months ago
Potential OA Treatment - Chemokine CCL17 Inhibition
Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in pain and disability, said researchers with the drug's developer.
https://t.co/MYYBBIIuDA https://t.co/1AfbxCuGIq
Dr. John Cush RheumNow
1 year 11 months ago
Heritability of asymptomatic ANA positivity is 25%. Asymptomatic ANA positive individuals did not exhibit increased cumulative genetic risk for lupus compared to ANA negative individuals. Genetic study of 1,955 asymptomatic ANA+ v 3,634 asymptomatic ANAnegs.… https://t.co/P0MmFfG7NV https://t.co/KnlyNPKG4s
Dr. John Cush RheumNow
1 year 11 months ago
Long-term Tofacitinib in Juvenile Idiopathic Arthritis
The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.
https://t.co/IKHM6z8iMB https://t.co/O6ig1lTQR4
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Dr. John Cush RheumNow
1 year 11 months ago
Relapse of idiopathic inflammatory myopathies (IIMs) was seen 65/105 (62%) pts. Higher risk seen w/ ANA positivity (HR 1.13), w/ + histopathology on muscle Bx (HR 1.69), & immunosuppressants use before relapse (HR 0.50). https://t.co/tr0OdvOAPK https://t.co/H3t3u1mDtd
Arthritis & Rheumatology reports that treatment trends in juvenile idiopathic arthritis (JIA) in the last two decades finds rising use of newer biologic and targeted synthetic DMARDs coupled with a decline in conventional DMARD use. Adalimumab is most used b/tsDMARD after csDMARDs.
